ArticleJournal of veterinary research2026
Pharmacokinetics and residue depletion of enrofloxacin and its metabolite ciprofloxacin in land snails
Article in Journal of veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The pharmacokinetics (PK) and tissue distribution of enrofloxacin (EF) and its main metabolite, ciprofloxacin (CP), were determined in land snails ( Material and Methods: In the single-dose regimen, snails received EF Results: Concentrations of EF in haemolymph after IHL administration remained above the limit of quantification up to 72 h post dose. Enrofloxacin had a 15-19 h elimination half-life. It was more bioavailable from medicated wafers (74.6%) than from gavage (27.7%); however, variability and small sample sizes prevented statistical analysis. Concentrations of CP were inconsistently detectable and often below quantification limits, suggesting limited EF biotransformation. After multiple dosing, EF accumulated predominantly in the hepatopancreas, and less in muscle, the albumen gland and mucus. Tissue contained detectable CP but haemolymph did not. Persistence of EF was noted in tissues beyond 240 h at concentrations often exceeding the 100-300 μg/kg maximum residue limits for other food-producing species. Conclusion: This preliminary study indicates that EF clears slowly and metabolises incompletely to CP in snails, resembling its PK patterns in aquatic and reptilian species. The persistence of EF in edible tissues suggests that withdrawal periods may need to be considerably longer than those for other terrestrial animals. Further depletion studies with extended sampling times, assessment of minimum inhibitory concentration values for snail pathogens and protein binding data are warranted to support safe and rational EF use in heliciculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.